Acadia Pharmaceuticals | ACAD - Equity Capital And Reserves



Acadia Pharmaceuticals reported $822.38M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Corcept Therapeutics USD 635.79M 47.49M Jun/2025
Cytokinetics USD -737440000 471.03M Jun/2025
Eisai JPY 828.51B 12.91B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Moderna USD 9.4B 667M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Prothena USD 324.33M 162.6M Jun/2025
PTC Therapeutics USD -206546000 20.79M Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025